Kang M and Chung RT (2007), The role of early viral decline in the treatment of hepatitis C in HIV-1 co-infected persons [Letter to the Editor], Journal of AIDS, Accepted.
Aweeka FT, Kang M, Yu J-Y, Lizak P, Alston B, Chung RT (2007), Pharmacokinetic evaluation of the effects of Ribavirin on Zidovudine triphosphate formation. HIV Medicine, Accepted.
Kang M, Lagakos SW (2007), Statistical methods for panel data from a semi-Markov process, with application to HPV. Biostatistics, In Press.
Blackard JT, Kang M, St.Clair JB, Lin W, Kamegaya Y, Sherman KE, Koziel MJ, Peters MG, Andersen J, Chung RT (2007), Viral factors associated with cytokine expression during HCV/HIV co-infection. Journal of Interferon and Cytokine Research, In Press.
Blackard JT, Kang M, Sherman KE, Koziel MJ, Peters MG, Chung RT (2006), Effects of HCV treatment on cytokine expression during HCV/HIV co-infection. Journal of Interferon and Cytokine Research, 26(11):834-838.
Liddicoat RV, Losina E, Kang M, Freedberg KA, Walensky RP (2006), Refusing HIV testing in an urgent care setting: results from the "Think HIV" program. AIDS Patient Care and STDs, 20(2):84-92.
Kang M, Lagakos SW (2004), Evaluation of log-rank test for infrequent observations from a multi-state process, with application to HPV vaccine efficacy. Statistics in Medicine, 23:3681-3696.
Kang M, Lagakos SW (2004), Evaluating the role of human papillomavirus vaccine in cervical cancer prevention. Statistical Methods in Medical Research, 13:139-155.
Borkowsky W, Fenton T, Wara D, McNamara J, Samson P, Kang M, Mofenson L, Cunningham C, Duliege, AM, Sinangil F, Spector SA, Jimenez E, Bryson Y, Burchett S, Frenkel LM, Yogev R, Gigliotti F, Luzuriaga K, Livingston RA and the AIDS Clinical Trials Group 230 Collaborators (2001), Human immunodeficiency virus type 1 (HIV-1) gp120 specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine, Journal of Infectious Diseases, 184:1331-1335.
Cunningham CK, Wara DW, Kang M, Fenton T, Hawkins E, McNamara J, Mofenson L, Duliege AM, Francis D, McFarland EJ, Borkowsky W (2001), Safety of two recombinant HIV-1 envelope vaccines in neonates born to HIV-1 infected women, Clinical Infectious Diseases, 32:801-807.
Borkowsky W, Wara D, Fenton T, McNamara J, Kang M, Mofenson L, McFarland E, Cunningham C, Duliege AM, Francis D, Bryson Y, Burchett S, Spector SA, Frenkle L, Starr S, Van Dyke R, Jimenez E and the AIDS Clinical Trial Group 230 Collaborators (2000), Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving GP120 vaccines, Journal of Infectious Diseases, 181:890-896.
Stiehm ER, Fletcher CV, Mofenson LM, Palumbo PE, Kang M, Fenton T, Sapan CV, Meyer WA, Shearer WT, Hawkins E, Fowler MG, Bouquin P, Purdue L, Sloand EM, Nemo GJ, Wara D, Bryson YJ, Starr SE, Petru A, and Burchett S for the Pediatric AIDS Clinical Trials Group 273 Study Group (2000), Use of HIV-IVIG in HIV-1 infected children, Journal of Infectious Diseases, 181:548-554.